Supplementary Figure 1 from Upregulation of ER Signaling as an Adaptive Mechanism of Cell Survival in HER2-Positive Breast Tumors Treated with Anti-HER2 Therapy
Mario Giuliano(Regione Campania), Rachel Schiff(Baylor College of Medicine), Jenny C. Chang(Baylor College of Medicine), Carmine De Angelis(Baylor College of Medicine), Gary C. Chamness(Baylor College of Medicine), Sabrina Herrera(Mayo Clinic), Alejandro Contreras(Baylor College of Medicine), C. Kent Osborne(Baylor College of Medicine), Joe W. Gray(Norwegian Cancer Society), Sufeng Mao(Baylor College of Medicine), Sara López‐Tarruella(Instituto de Salud Carlos III), Meghana V. Trivedi(University of Houston), Agostina Nardone(AstraZeneca (Spain)), Xiaoyong Fu(King University), Yen-Chao Wang(Baylor College of Medicine), Mothaffar F. Rimawi(Baylor College of Medicine), Susan G. Hilsenbeck(Baylor College of Medicine), Anne C. Pavlick(Baylor College of Medicine), Laura M. Heiser(Oregon Health & Science University), Tao Wang(Pfizer (United States)), Huizhong Hu(Baylor College of Medicine), Nicholas J. Wang(Oregon Health & Science University), Carolina Gutiérrez(Baylor College of Medicine)
Cited by 0
Related Papers
Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features
|Proceedings of the National Academy of Sciences|2009|1.4k
Targeting Wnt-driven cancer through the inhibition of Porcupine by LGK974
|Proceedings of the National Academy of Sciences|2013|833
Targeting cardiac fibrosis with engineered T cells
|Nature|2019|799
The Human Tumor Atlas Network: Charting Tumor Transitions across Space and Time at Single-Cell Resolution
|Cell|2020|602
Prognostically relevant gene signatures of high-grade serous ovarian carcinoma
|Journal of Clinical Investigation|2012|591